Cite
HARVARD Citation
Torgauten, H. et al. (2021). Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study. Multiple sclerosis journal, experimental, translational and clinical. 7 (1), p. . [Online].